Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Fourth Military Medical University
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Apr 13, 2024
Discovery & Translation
Science spotlight: Tumors siphon taurine from T cells, and Revolution’s RAS (ON) inhibitors
BioCentury’s roundup of translational innovations
BioCentury | Mar 8, 2024
Discovery & Translation
Distillery spotlight: new ubiquitin-modulating mechanisms from academia
Innovators are finding new ways of targeting E3 ligases and DUBs in liver diseases and cancer: BioCentury’s survey of the 2023 translational literature
BioCentury | Feb 10, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into neurology
Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
BioCentury | Jul 30, 2021
Distillery Therapeutics
Peptide inhibitor of LY96 for ischemic and hemorrhagic stroke
DISEASE CATEGORY: Neurology
INDICATION: Stroke A peptide targeting the TLR4 ligand LY96 could treat ischemic and hemorrhagic stroke. The peptide — comprising a domain of the LY96 binding
INDICATION: Stroke A peptide targeting the TLR4 ligand LY96 could treat ischemic and hemorrhagic stroke. The peptide — comprising a domain of the LY96 binding
BioCentury | Mar 25, 2020
Product Development
COVID-19 roundup: Emergency use of Moderna vaccine could come earlier than expected; plus ASCO goes virtual, Galapagos pauses filgotinib trials and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Mar 20, 2020
Translation in Brief
Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar
BioCentury’s roundup of preclinical news
BioCentury | Aug 22, 2019
Distillery Therapeutics
Treating carbapenem-resistant bacteria with the insect-derived thanatin
Items per page:
1 - 10 of 13